Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Locally Advanced Gastric Cancer

Last updated: April 10, 2020
Sponsor: Wuhan University
Overall Status: Active - Recruiting

Phase

2

Condition

Digestive System Neoplasms

Stomach Cancer

Gastric Cancer

Treatment

N/A

Clinical Study ID

NCT04345770
WuhanZN_HIPEC
  • Ages 18-75
  • All Genders

Study Summary

The efficacy of HIPEC in prevention of local recurrence, distant metastasis or peritoneal metastasis in locally advanced gastric cancer is not definite. The hypothesis of the trial is that radical gastrectomy combined with HIPEC is superior to only radical gastrectomy in terms of overall survival.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Histological proved diagnosis of locally advanced gastric cancer.

  • No evidence of distant metastases or peritoneal metastases.

  • Preoperative examination (CT/MRI) demonstrated resectable gastric cancer with T3-T4stage.

  • Eligible for radical gastrectomy with D2 lymphadenectomy.

  • Have not received cytotoxic chemotherapy or radiotherapy.

  • Written informed consent is obtained prior to commencement of trial treatment.

Exclusion

Exclusion Criteria:

  • Existence of distant metastasis or peritoneal metastasis during surgery (M1).

  • Any previous chemotherapy or radiotherapy

  • Active systemic infections

  • Inadequate cardiac function, renal function, liver function or bone marrow function atthe beginning of the trial.

  • Female patients who are pregnant or breast feeding

Study Design

Total Participants: 100
Study Start date:
April 01, 2020
Estimated Completion Date:
May 31, 2025

Study Description

To determine the efficacy of HIPEC in the treatment of locally advanced gastric cancer, patients are randomized into HIPEC group and control group. In HIPEC group, the patients undergo neoadjuvant chemotherapy followed by radical gastrectomy with D2 lymphadenectomy and HIPEC with paclitaxel and 5-Fu. Patients in the control group just undergo neoadjuvant chemotherapy followed by radical gastrectomy with D2 lymphadenectomy. Patients in both groups receive postoperative chemotherapy (6 circles together with neoadjuvant chemotherapy) and are followed up for 5 years or until death.

The trial is designed as a prospective, randomized, open and parallel group study.

Connect with a study center

  • Wuhan University

    Wuhan, Hubei
    China

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.